A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab in Combination With Other Anti-cancer Therapies in Participants With Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Cemiplimab (Primary) ; Isatuximab (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sanofi
- 02 Oct 2019 Planned primary completion date changed from 1 May 2023 to 1 Jul 2023.
- 25 Jul 2019 Planned End Date changed from 1 Jan 2023 to 1 May 2023.
- 25 Jul 2019 Planned primary completion date changed from 1 Jan 2023 to 1 May 2023.